These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A. J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893 [Abstract] [Full Text] [Related]
3. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G. Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547 [Abstract] [Full Text] [Related]
4. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S. J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233 [Abstract] [Full Text] [Related]
7. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Arthritis Res Ther; 2019 May 10; 21(1):118. PubMed ID: 31077258 [Abstract] [Full Text] [Related]
8. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J. J Am Acad Dermatol; 2016 Jan 10; 74(1):134-42. PubMed ID: 26549249 [Abstract] [Full Text] [Related]
9. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Deeks ED. Drugs; 2015 Aug 10; 75(12):1393-403. PubMed ID: 26220911 [Abstract] [Full Text] [Related]
12. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients. Wells AF, Edwards CJ, Kivitz AJ, Bird P, Guerette B, Delev N, Paris M, Teng L, Aelion JA. Rheumatology (Oxford); 2022 Mar 02; 61(3):1035-1043. PubMed ID: 34100922 [Abstract] [Full Text] [Related]
14. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. J Eur Acad Dermatol Venereol; 2017 Mar 02; 31(3):507-517. PubMed ID: 27768242 [Abstract] [Full Text] [Related]